TNYA

Over the past six months, Tenaya Therapeutics' stock price has been impacted by several events. In September 2026, the company received U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401, leading to a +7.95% stock increase. In August 2026, significant financial underperformance in Q2 2026, including a net loss of $43.39 million and missed collaboration revenue, caused a stock decline of approximately 7.51% on the day and about 20% since May 31, 2026. May 2026 saw positive gene therapy data with early heart rhythm improvements. In March 2026, a research collaboration with Alnylam Pharmaceuticals to identify new cardiovascular drug targets resulted in a stock jump of +40.9%. Despite these movements, the stock price has experienced a significant overall decline, losing 44.1% over the past 12 months as of September 15, 2026, and 46.79% from September 16, 2025, to September 15, 2026. A key risk impacting the stock is the potential for clinical and regulatory setbacks, such as a recent clinical hold placed on its TN-201 program.